# Hair loss treatment guidance

> Live situation record from CLSTR: https://clstr.news/situations/hair-loss-treatment-guidance
> Updated: 2026-07-27T18:42:39.000Z. Sources: 2. Developments: 2.

Early coverage noted the growing interest in minoxidil gummy formulations for thinning hair. Subsequent reporting expanded the discussion, outlining the primary biological driver of androgenetic alopecia—dihydrotestosterone (DHT) and genetic susceptibility. It highlighted the large number of affected individuals in the United States and detailed how the hormone shortens the hair growth phase. FDA‑approved options such as topical minoxidil and oral finasteride were reaffirmed, while the effectiveness of newer approaches like platelet‑rich plasma (PRP) therapy was qualified, emphasizing strict treatment schedules and realistic expectations. Experts stressed the importance of accurate diagnosis using standard scales (Norwood for men, Ludwig for women) to guide appropriate interventions and manage patient expectations.

## Timeline

### 2026-07-27: Hair loss treatment guidance highlights genetics and PRP pitfalls

Hair loss, driven by genetics and DHT, impacts millions; FDA‑approved minoxidil and finasteride are available, while PRP therapy requires consistent sessions and realistic expectations.

2 sources. https://clstr.news/cluster/hair-loss-treatment-guidance-highlights-genetics-and-prp-pitfalls

### 2026-07-07: Hair Thinning Causes and Minoxidil Gummy Treatment

Hair thinning is gradual, driven by genetics, age, hormones, stress, and nutrition. Low‑dose oral minoxidil gummies, repurposed from hypertension medication, can boost hair density but may cause side effects, ​

2 sources. https://clstr.news/cluster/hair-thinning-causes-and-minoxidil-gummy-treatment

---
Cite as: Hair loss treatment guidance. CLSTR, https://clstr.news/situations/hair-loss-treatment-guidance